2013年第三季度制药及保健市场研究报告——Hong Kong Pharmaceuticals and Healthcare Report Q3 2013

纸介版价格:美元/篇 页数:111页上传日期:2013-07-10
电子版价格:1295美元/篇
纸介版+电子版价格:美元 附件下载:               
关键字: |Pharmaceuticals and Healthcare|

2013-5-22


Abstract

BMI View: Hong Kong's attractiveness as a pharmaceutical market hinges largely on its ageing and
affluent demographics, its proximity to China as well as the stable political and economic environment.
However we highlight that its long-term attractiveness is limited by its small market size and the increasing
openness of the Chinese market, which decreases the necessity for firms to set up bases in Hong Kong.
Headline Expenditure Projections
■ Pharmaceuticals: HKD10.31bn (US$1.33bn) in 2012 to HKD10.77bn (US$1.39bn) in 2013; +4.5% in
local currency terms and +4.3% in US dollar terms. Forecast broadly in line with Q212.
■ Healthcare: HKD112.38bn (US$14.49bn) in 2012 to HKD120.83bn (US$15.55bn) in 2013; +7.5% in
local currency terms and +7.3% in US dollar terms. Forecast broadly in line with Q212.

Table of Contents

BMI Industry View ... 7
SWOT  9
Political . 11
Economic ..... 12
Business Environment  13
Industry Forecast .. 14
Pharmaceutical Market Forecast .... 14
Table: Pharmaceutical Sales Indicators, 2009-2017. . 14
Healthcare Market Forecast .... 15
Table: Healthcare Expenditure Indicators Based On Government Sources, 2009-2017 . . 17
Table: Healthcare Governmental Indicators Based On Government Sources, 2009-2017 17
Table: Healthcare Private Indicators Based On Government Sources, 2009-2017   18
Prescription Market Forecast .. 19
Table: Prescription Drug Sales Indicators, 2009-201720
Patented Drug Market Forecast ..... 20
Table: Patented Drug Market Indicators, 2009-2017. . 21
Generic Drug Market Forecast  22
Table: Generic Drug Sales Indicators, 2009-2017 23
OTC Medicine Market Forecast ..... 24
Table: OTC Medicine Sales Indicators, 2009-2017. . . 26
Pharmaceutical Trade Forecast ..... 26
Table: Exports and Imports Indicators, 2009-2017 27
Other Healthcare Data ..... 28
Key Risks To BMI's Forecast Scenario ... 29
Macroeconomic Forecasts ..... 31
Economic Analysis ..... 31
Supportive Pressures Still Intact ... 32
...But So Are Corrective Risks . 33
Fundamentals Buttress Long-Term Appreciation  34
Expenditure Breakdown .. 34
Private Consumption  34
Government Consumption  34
Gross Fixed Capital Formation .... 35
Net Exports . 35
Industry Risk Reward Ratings  36
Asia Pacific Risk/Reward Ratings ... 36
Hong Kong Pharmaceutical Risk/Reward Ratings  41
Rewards ..... 41
Risks .... 41
Market Overview ... 43
Industry Trends And Developments .. 45
Epidemiology .... 45
Healthcare Sector .... 49
Healthcare Financing ..... 51
Healthcare Insurance  53
Biotechnology ... 55
Clinical Trials ... 58
Regulatory Development .. 60
Regulatory Regime ... 60
Table: Processed Applications . . 61
Regulatory Developments  62
Pharmaceutical Trade Regulations  64
Intellectual Property Issues .... 64
Counterfeit Drugs .... 65
Pricing And Reimbursement Regime .... 66
Competitive Landscape .... 68
Pharmaceutical Industry . 68
Traditional Chinese Medicine . 69
Industry Developments .... 70
Pharmaceutical Supply Chain  71
Retail Pharmacy Sector ... 72
Company Profile .... 74
Wuyi ..... 74
CK Life Sciences . 77
South Asia Pharmamedic .. 81
C&Y Pharmaceutical Investment .... 82
Vida Laboratories  84
GSK  87
Pfizer .... 90
Sanofi .... 93
Merck & Co .. 96
Novartis . 98
Demographic Forecast ... 101
Table: Hong Kong's Population By Age Group, 1990-2020 ('000) . . . 102
Table: Hong Kong's Population By Age Group, 1990-2020 (% of total). 103
Table: Hong Kong's Key Population Ratios, 1990-2020    . 104
Table: Hong Kong's Rural And Urban Population, 1990-2020  . . . 104
Glossary ... 105
Methodology .. 107
Pharmaceutical Expenditure Forecast Model .. 107
Healthcare Expenditure Forecast Model ... 107
Notes On Methodology .. 108
Risk/Reward Ratings Methodology .... 109
Ratings Overview ... 110
Table: Pharmaceutical Risk/Reward Ratings Indicators    . . 110
Indicator Weightings .... 111

定购方法
① 注册订购:
点击在线订购进行报告订购
我们的服务人员将在24小时内与您联系。

② 电话订购:
拔打电话
北京:400 0090050   010-82863481
24小时:13436696826
传真:010-82601570

上海:021-64871266
021-64872612
24小时:13524982235
传真:021-64872324

签订协议
可从网上下载报告订购表或由我们传真报告订购表或订购协议。
传真:010-82601570

付款方式
① 通过银行转帐的形式支付报告购买款项
② 我们收到款项后,24小时内快递报告或者发送报告邮件

③ 款项到帐后快递发票

银行电汇:
北京:
开户行:
上海浦东发展银行北京知春路支行
帐号:91170154740001300
户名:北京佐思信息咨询有限责任公司
外币汇款账户信息:
BENEFICIARY’S BANK (受益人银行名称):
SHANGHAI PUDONG DEVELOPMENT BANK, H.O. SHANGHAI, CHINA
SWIFT:
SPDBCNSH390
BENEFICIARY’S A/C NO. (受益人帐号):
911 701 547 4000 1300
BENEFICIARY’S NAME(受益人名称):
OKOKOK(ZUOSI) Information Consulting CO.,LTD
COMPANY ADDRESS:
Room 1008, Tower A2, Longrange World Office Building, No.18 Suzhou Street, Haidian District, Beijing China
REMARKS(附言):
SHANGHAI PUDONG DEVELOPMENT BANK, BEIJING BR.***SUB-BR
在线客服系统